While transcatheter PDA (tcPDA) occlusion has been a mainstay of congenital interventional cardiology practice for decades, very low birth weight infants were historically excluded from consideration due to vascular access limitations and lack of appropriately sized devices.

Recent technological advances culminated in FDA approval of the first PDA occlusion device for low birth -weight infants in 2019. The subsequent five years have seen rapid uptake of tcPDA occlusion in this population, such that catheter-based procedures have overtaken surgical ligation at an increasing number of centers. Short-term outcomes have been favorable, but enduring success requires knowledge and implementation of procedure-specific best practices.

This Society of Cardiovascular Angiography and Interventions (SCAI) position statement addresses patient selection considerations, optimal procedural and technical considerations, operator training and competency, and institutional factors for programmatic success.

All authors: Brent M. Gordon, MD, FSCAI; Dana Boucek, MD; Tacy Downing, MD; Timothy Head, DO; Carrie Herbert, MD, FSCAI; Philip Levy, MD; R. Allen Ligon, MD, FSCAI; Souvik Mitra, MD; Arash Salavitabar, MD, FSCAI; Shyam Sathanandam, MD, FSCAI; Nathaniel Taggart, MD, FSCAI; Jenny Zablah, MD, FSCAI; Evan Zahn, MD, MSCAI; Sarosh P. Batlivala, MD, MSCI, FSCAI(Co-Chair).